MetLife (MET) Stock Looks Below Fair Value Even After A 79% Run
MetLife stock has delivered a strong 5 year run, yet the valuation work sends mixed signals, with the Excess Returns intrinsic value estimate pointing to upside while market multiples lean the other way.
- The shares are up 79.2% over 5 years, which puts MetLife in the camp of insurers where past returns already bake in a lot of optimism.
- Fresh capital raised at Chariot Re, where MetLife is a sponsor, can support growth in life and annuity reinsurance. Any mispricing of long dated liabilities remains a key risk for how investors value those cash flows.
- The broader checks lean expensive, with MetLife scoring 2 out of 6 on value screens even though the Excess Returns model suggests the stock trades at a discount to its intrinsic value.
The issue now is whether MetLife's recent track record and capital deployment story justify paying what looks like a full market multiple when the intrinsic value estimate still flags potential upside.
Spot similar valuation puzzles by scanning our curated list of 31 high quality undervalued stocks, which combines strong fundamentals with prices the market has not fully recognized yet.Does MetLife Look Undervalued on Excess Returns?
The Excess Returns approach looks at how much profit MetLife earns on its equity base above the return that shareholders require. For MetLife, the model leans on a Book Value of $43.03 per share and a Stable EPS estimate of $8.42 per share, which are both derived from analyst expectations for future return on equity. With an Average Return on Equity of 15.83% and a Cost of Equity of $3.97 per share, the implied Excess Return of $4.44 per share suggests the business is earning more than its equity charge on a sustained basis.
Feeding these inputs into the Excess Returns framework, along with a Stable Book Value of $53.18 per share, produces an estimated intrinsic value of $171.01 per share. Compared with the current share price, that implies MetLife screens about 44.0% undervalued on this method. The recent $700m capital raise at Chariot Re gives extra context, because the expansion of life and annuity reinsurance can increase the importance of getting long dated liability pricing right for this intrinsic value to hold.
On this model, MetLife stock appears undervalued relative to what its excess returns on equity imply.
Our Excess Returns analysis suggests MetLife is undervalued by 44.0%. Track this in your watchlist or portfolio, or discover 31 more high quality undervalued stocks.
Is MetLife Getting Expensive on Earnings?
The P/E ratio suits MetLife because earnings are a core anchor for how insurers are valued. On this metric, the stock trades on about 17.7x, which is above both the broader Insurance industry average of 11.2x and the peer group around 14.7x.
A fair P/E multiple that adjusts for MetLife’s size, risk profile and profitability sits nearer 14.4x. That is a clear gap to the current 17.7x, which indicates investors are already paying a premium relative to what this framework implies for the business.
On this P/E perspective, MetLife stock appears more expensive compared with both its tailored fair multiple and the going rate for insurers.
See what the numbers say about this price — find out in our valuation breakdown.
The MetLife Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this MetLife valuation puzzle leaves off and spell out which paths for future growth, profitability and earnings would need to play out for the shares to be worth significantly more or less than today’s price. Each narrative links its number to a clear view on how MetLife's growth, margins and key risks might evolve, giving you something concrete to revisit as new information arrives on the Community page.
You can be one of the first voices in the Simply Wall St community to set out a number driven Narrative on MetLife, including a clear view on whether Chariot Re’s US$700m expansion actually creates value for shareholders over time.
Lay out your case and link it to the metrics that matter, then track how it holds up as new results and reinsurance updates come through.
Do you think there's more to the story for MetLife? Head over to our Community to see what others are saying!
The Bottom Line
MetLife looks like a genuine valuation puzzle. The intrinsic value work built on Excess Returns points to a meaningful discount, while the P/E view suggests the stock already trades on a premium versus insurers and its own tailored multiple. Broader checks come through as weak, which tempers how much weight you might put on that single intrinsic value signal.
Everything comes back to one question. Does MetLife earn enough on its equity and reinsurance capital, including at Chariot Re, to justify both the current premium multiple and the intrinsic value upside, or is the market simply charging a high price for those long dated risks?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com